Visudyne Provides Test-Case For Medicare Coverage Of Off-Label Indications
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services plans to ask investigators for unpublished information from a peer-reviewed study of QLT PhotoTherapeutic's Visudyne (verteporfin) before moving forward with its decision to expand coverage to off-label indications for age-related macular degeneration (AMD)
You may also be interested in...
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
CMS Denial Of Visudyne Coverage Would Give Physicians No Option – Society
A CMS denial of coverage for Visudyne (verteporfin) therapy for certain age-related blindness patients would have the effect of forcing physicians to conduct unethical trials, The Vitreous Society maintains in recent comments to the agency